nodes	percent_of_prediction	percent_of_DWPC	metapath
Mesalazine—PPARG—dermis—systemic scleroderma	0.0212	0.108	CbGeAlD
Mesalazine—PTGS2—skeletal joint—systemic scleroderma	0.00936	0.0477	CbGeAlD
Mesalazine—MPO—artery—systemic scleroderma	0.00864	0.044	CbGeAlD
Mesalazine—PPARG—artery—systemic scleroderma	0.00766	0.0391	CbGeAlD
Mesalazine—MPO—endothelium—systemic scleroderma	0.0073	0.0372	CbGeAlD
Mesalazine—CHUK—connective tissue—systemic scleroderma	0.00724	0.0369	CbGeAlD
Mesalazine—MPO—blood vessel—systemic scleroderma	0.00673	0.0343	CbGeAlD
Mesalazine—CHUK—skin of body—systemic scleroderma	0.00653	0.0333	CbGeAlD
Mesalazine—PPARG—endothelium—systemic scleroderma	0.00647	0.033	CbGeAlD
Mesalazine—PPARG—blood vessel—systemic scleroderma	0.00597	0.0304	CbGeAlD
Mesalazine—CHUK—digestive system—systemic scleroderma	0.00523	0.0267	CbGeAlD
Mesalazine—IKBKB—connective tissue—systemic scleroderma	0.00492	0.0251	CbGeAlD
Mesalazine—IKBKB—smooth muscle tissue—systemic scleroderma	0.0045	0.0229	CbGeAlD
Mesalazine—IKBKB—skin of body—systemic scleroderma	0.00444	0.0227	CbGeAlD
Mesalazine—CHUK—lung—systemic scleroderma	0.00437	0.0223	CbGeAlD
Mesalazine—PTGS1—artery—systemic scleroderma	0.0041	0.0209	CbGeAlD
Mesalazine—ALOX5—connective tissue—systemic scleroderma	0.00408	0.0208	CbGeAlD
Mesalazine—PTGS2—Fluocinonide—Mometasone—systemic scleroderma	0.00394	0.624	CbGdCrCtD
Mesalazine—PTGS2—artery—systemic scleroderma	0.00392	0.02	CbGeAlD
Mesalazine—ALOX5—smooth muscle tissue—systemic scleroderma	0.00373	0.019	CbGeAlD
Mesalazine—IKBKB—digestive system—systemic scleroderma	0.00355	0.0181	CbGeAlD
Mesalazine—PTGS1—endothelium—systemic scleroderma	0.00346	0.0176	CbGeAlD
Mesalazine—MPO—connective tissue—systemic scleroderma	0.00345	0.0176	CbGeAlD
Mesalazine—IKBKB—tendon—systemic scleroderma	0.00338	0.0172	CbGeAlD
Mesalazine—PTGS2—endothelium—systemic scleroderma	0.00331	0.0169	CbGeAlD
Mesalazine—PTGS1—blood vessel—systemic scleroderma	0.00319	0.0163	CbGeAlD
Mesalazine—MPO—skin of body—systemic scleroderma	0.00311	0.0159	CbGeAlD
Mesalazine—PPARG—connective tissue—systemic scleroderma	0.00306	0.0156	CbGeAlD
Mesalazine—PTGS2—blood vessel—systemic scleroderma	0.00305	0.0156	CbGeAlD
Mesalazine—IKBKB—lung—systemic scleroderma	0.00297	0.0151	CbGeAlD
Mesalazine—ALOX5—digestive system—systemic scleroderma	0.00294	0.015	CbGeAlD
Mesalazine—PPARG—smooth muscle tissue—systemic scleroderma	0.0028	0.0143	CbGeAlD
Mesalazine—PPARG—skin of body—systemic scleroderma	0.00276	0.0141	CbGeAlD
Mesalazine—MPO—digestive system—systemic scleroderma	0.00249	0.0127	CbGeAlD
Mesalazine—ALOX5—lung—systemic scleroderma	0.00246	0.0125	CbGeAlD
Mesalazine—PTGS2—Fluticasone Propionate—Mometasone—systemic scleroderma	0.00238	0.376	CbGdCrCtD
Mesalazine—PPARG—digestive system—systemic scleroderma	0.00221	0.0113	CbGeAlD
Mesalazine—PPARG—tendon—systemic scleroderma	0.0021	0.0107	CbGeAlD
Mesalazine—MPO—lung—systemic scleroderma	0.00208	0.0106	CbGeAlD
Mesalazine—PPARG—lung—systemic scleroderma	0.00185	0.00942	CbGeAlD
Mesalazine—PTGS1—connective tissue—systemic scleroderma	0.00164	0.00835	CbGeAlD
Mesalazine—PTGS2—connective tissue—systemic scleroderma	0.00156	0.00798	CbGeAlD
Mesalazine—PTGS1—smooth muscle tissue—systemic scleroderma	0.0015	0.00763	CbGeAlD
Mesalazine—PTGS1—skin of body—systemic scleroderma	0.00148	0.00754	CbGeAlD
Mesalazine—IKBKB—TCR signaling in naïve CD4+ T cells—CSK—systemic scleroderma	0.00147	0.00703	CbGpPWpGaD
Mesalazine—IKBKB—BCR signaling pathway—CSK—systemic scleroderma	0.00146	0.00695	CbGpPWpGaD
Mesalazine—PTGS2—smooth muscle tissue—systemic scleroderma	0.00143	0.0073	CbGeAlD
Mesalazine—PTGS2—skin of body—systemic scleroderma	0.00141	0.0072	CbGeAlD
Mesalazine—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—MMP1—systemic scleroderma	0.00141	0.00673	CbGpPWpGaD
Mesalazine—IKBKB—IL1-mediated signaling events—IL1A—systemic scleroderma	0.0014	0.00666	CbGpPWpGaD
Mesalazine—MPO—Vitamin B12 Metabolism—CCL2—systemic scleroderma	0.0014	0.00666	CbGpPWpGaD
Mesalazine—CHUK—Downstream TCR signaling—HLA-DQB1—systemic scleroderma	0.0014	0.00666	CbGpPWpGaD
Mesalazine—IKBKB—TCR signaling in naïve CD4+ T cells—CD247—systemic scleroderma	0.00139	0.00661	CbGpPWpGaD
Mesalazine—MPO—IL23-mediated signaling events—IL1B—systemic scleroderma	0.00137	0.00653	CbGpPWpGaD
Mesalazine—CHUK—Interleukin-1 signaling—IL1A—systemic scleroderma	0.00135	0.00645	CbGpPWpGaD
Mesalazine—CHUK—Apoptosis—IRF5—systemic scleroderma	0.00132	0.00629	CbGpPWpGaD
Mesalazine—PTGS1—Prostaglandin Synthesis and Regulation—EDN1—systemic scleroderma	0.00128	0.0061	CbGpPWpGaD
Mesalazine—IKBKB—Downstream TCR signaling—HLA-DQB1—systemic scleroderma	0.00127	0.00604	CbGpPWpGaD
Mesalazine—CHUK—RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways—TNFAIP3—systemic scleroderma	0.00123	0.00586	CbGpPWpGaD
Mesalazine—IKBKB—Interleukin-1 signaling—IL1A—systemic scleroderma	0.00123	0.00585	CbGpPWpGaD
Mesalazine—PPARG—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CD40LG—systemic scleroderma	0.0012	0.00572	CbGpPWpGaD
Mesalazine—IKBKB—Apoptosis—IRF5—systemic scleroderma	0.0012	0.00571	CbGpPWpGaD
Mesalazine—CHUK—TCR Signaling Pathway—CD247—systemic scleroderma	0.00119	0.00569	CbGpPWpGaD
Mesalazine—CHUK—Integrated Breast Cancer Pathway—SMAD7—systemic scleroderma	0.00119	0.00568	CbGpPWpGaD
Mesalazine—CHUK—Structural Pathway of Interleukin 1 (IL-1)—IL1A—systemic scleroderma	0.00119	0.00567	CbGpPWpGaD
Mesalazine—PTGS1—digestive system—systemic scleroderma	0.00118	0.00603	CbGeAlD
Mesalazine—CHUK—GAB1 signalosome—CSK—systemic scleroderma	0.00115	0.00548	CbGpPWpGaD
Mesalazine—MPO—Folate Metabolism—CCL2—systemic scleroderma	0.00114	0.00542	CbGpPWpGaD
Mesalazine—PPARG—Circadian rythm related genes—TOP1—systemic scleroderma	0.00113	0.0054	CbGpPWpGaD
Mesalazine—PTGS2—digestive system—systemic scleroderma	0.00113	0.00576	CbGeAlD
Mesalazine—CHUK—Toll-like Receptor Signaling Pathway—IRF5—systemic scleroderma	0.00113	0.00539	CbGpPWpGaD
Mesalazine—PTGS1—tendon—systemic scleroderma	0.00112	0.00574	CbGeAlD
Mesalazine—IKBKB—RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways—TNFAIP3—systemic scleroderma	0.00111	0.00531	CbGpPWpGaD
Mesalazine—CHUK—Integrated Pancreatic Cancer Pathway—TOP1—systemic scleroderma	0.00111	0.00528	CbGpPWpGaD
Mesalazine—CHUK—TNF alpha Signaling Pathway—TNFAIP3—systemic scleroderma	0.0011	0.00524	CbGpPWpGaD
Mesalazine—CHUK—Osteopontin-mediated events—MMP2—systemic scleroderma	0.00108	0.00518	CbGpPWpGaD
Mesalazine—IKBKB—TCR Signaling Pathway—CD247—systemic scleroderma	0.00108	0.00516	CbGpPWpGaD
Mesalazine—IKBKB—Structural Pathway of Interleukin 1 (IL-1)—IL1A—systemic scleroderma	0.00108	0.00514	CbGpPWpGaD
Mesalazine—PTGS2—tendon—systemic scleroderma	0.00108	0.00548	CbGeAlD
Mesalazine—MPO—Vitamin B12 Metabolism—IL1B—systemic scleroderma	0.00106	0.00505	CbGpPWpGaD
Mesalazine—CHUK—IL-1 signaling pathway—IL1A—systemic scleroderma	0.00105	0.005	CbGpPWpGaD
Mesalazine—CHUK—TCR signaling—HLA-DQB1—systemic scleroderma	0.00104	0.00498	CbGpPWpGaD
Mesalazine—CHUK—B Cell Receptor Signaling Pathway—BLK—systemic scleroderma	0.00104	0.00496	CbGpPWpGaD
Mesalazine—PTGS2—Calcium signaling in the CD4+ TCR pathway—CD40LG—systemic scleroderma	0.00103	0.00492	CbGpPWpGaD
Mesalazine—IKBKB—Toll-like Receptor Signaling Pathway—IRF5—systemic scleroderma	0.00102	0.00489	CbGpPWpGaD
Mesalazine—PTGS2—Prostaglandin Synthesis and Regulation—EDN1—systemic scleroderma	0.00101	0.00484	CbGpPWpGaD
Mesalazine—IKBKB—TNF alpha Signaling Pathway—TNFAIP3—systemic scleroderma	0.000995	0.00475	CbGpPWpGaD
Mesalazine—IKBKB—Apoptosis Modulation and Signaling—BLK—systemic scleroderma	0.000992	0.00473	CbGpPWpGaD
Mesalazine—PTGS1—lung—systemic scleroderma	0.000987	0.00503	CbGeAlD
Mesalazine—IKBKB—IL-1 signaling pathway—IL1A—systemic scleroderma	0.000951	0.00454	CbGpPWpGaD
Mesalazine—IKBKB—TCR signaling—HLA-DQB1—systemic scleroderma	0.000946	0.00451	CbGpPWpGaD
Mesalazine—PTGS2—lung—systemic scleroderma	0.000944	0.00481	CbGeAlD
Mesalazine—IKBKB—B Cell Receptor Signaling Pathway—BLK—systemic scleroderma	0.000942	0.0045	CbGpPWpGaD
Mesalazine—CHUK—Toll Like Receptor 4 (TLR4) Cascade—ITGAM—systemic scleroderma	0.000935	0.00446	CbGpPWpGaD
Mesalazine—PPARG—PPARA activates gene expression—CTGF—systemic scleroderma	0.000903	0.00431	CbGpPWpGaD
Mesalazine—MPO—Selenium Micronutrient Network—CCL2—systemic scleroderma	0.000902	0.00431	CbGpPWpGaD
Mesalazine—IKBKB—GMCSF-mediated signaling events—CCL2—systemic scleroderma	0.000898	0.00428	CbGpPWpGaD
Mesalazine—CHUK—TWEAK Signaling Pathway—CCL2—systemic scleroderma	0.000894	0.00427	CbGpPWpGaD
Mesalazine—PPARG—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—CTGF—systemic scleroderma	0.000884	0.00422	CbGpPWpGaD
Mesalazine—CHUK—Regulation of toll-like receptor signaling pathway—IRF5—systemic scleroderma	0.000881	0.00421	CbGpPWpGaD
Mesalazine—MPO—Folate Metabolism—IL1B—systemic scleroderma	0.000862	0.00411	CbGpPWpGaD
Mesalazine—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CTLA4—systemic scleroderma	0.000857	0.00409	CbGpPWpGaD
Mesalazine—ALOX5—Selenium Micronutrient Network—CCL2—systemic scleroderma	0.000852	0.00406	CbGpPWpGaD
Mesalazine—IKBKB—Toll Like Receptor 4 (TLR4) Cascade—ITGAM—systemic scleroderma	0.000848	0.00405	CbGpPWpGaD
Mesalazine—CHUK—Toll-Like Receptors Cascades—ITGAM—systemic scleroderma	0.000833	0.00397	CbGpPWpGaD
Mesalazine—PPARG—RXR and RAR heterodimerization with other nuclear receptor—TGFB1—systemic scleroderma	0.000824	0.00393	CbGpPWpGaD
Mesalazine—PTGS2—C-MYB transcription factor network—COL1A2—systemic scleroderma	0.000822	0.00392	CbGpPWpGaD
Mesalazine—CHUK—Osteopontin-mediated events—MMP9—systemic scleroderma	0.000815	0.00389	CbGpPWpGaD
Mesalazine—IKBKB—TWEAK Signaling Pathway—CCL2—systemic scleroderma	0.000811	0.00387	CbGpPWpGaD
Mesalazine—CHUK—IL1-mediated signaling events—IL1B—systemic scleroderma	0.000803	0.00383	CbGpPWpGaD
Mesalazine—IKBKB—Regulation of toll-like receptor signaling pathway—IRF5—systemic scleroderma	0.000799	0.00381	CbGpPWpGaD
Mesalazine—PTGS2—Spinal Cord Injury—TNFSF13—systemic scleroderma	0.000798	0.00381	CbGpPWpGaD
Mesalazine—CHUK—Regulation of toll-like receptor signaling pathway—TNFAIP3—systemic scleroderma	0.000789	0.00376	CbGpPWpGaD
Mesalazine—IKBKB—Toll-Like Receptors Cascades—ITGAM—systemic scleroderma	0.000755	0.0036	CbGpPWpGaD
Mesalazine—CHUK—MicroRNAs in cardiomyocyte hypertrophy—EDN1—systemic scleroderma	0.000751	0.00359	CbGpPWpGaD
Mesalazine—CHUK—Signaling by EGFR—CSK—systemic scleroderma	0.000732	0.00349	CbGpPWpGaD
Mesalazine—IKBKB—IL1-mediated signaling events—IL1B—systemic scleroderma	0.000728	0.00348	CbGpPWpGaD
Mesalazine—CHUK—Signaling by EGFR in Cancer—CSK—systemic scleroderma	0.000725	0.00346	CbGpPWpGaD
Mesalazine—CHUK—IL-1 signaling pathway—CCL2—systemic scleroderma	0.000721	0.00344	CbGpPWpGaD
Mesalazine—IKBKB—Regulation of toll-like receptor signaling pathway—TNFAIP3—systemic scleroderma	0.000715	0.00341	CbGpPWpGaD
Mesalazine—PTGS2—Spinal Cord Injury—SELP—systemic scleroderma	0.000712	0.0034	CbGpPWpGaD
Mesalazine—CHUK—TCR Signaling Pathway—IL1A—systemic scleroderma	0.000707	0.00337	CbGpPWpGaD
Mesalazine—CHUK—Interleukin-1 signaling—IL1B—systemic scleroderma	0.000705	0.00337	CbGpPWpGaD
Mesalazine—CHUK—NOD pathway—IL1B—systemic scleroderma	0.000692	0.0033	CbGpPWpGaD
Mesalazine—MPO—Selenium Micronutrient Network—IL1B—systemic scleroderma	0.000684	0.00327	CbGpPWpGaD
Mesalazine—IKBKB—MicroRNAs in cardiomyocyte hypertrophy—EDN1—systemic scleroderma	0.000681	0.00325	CbGpPWpGaD
Mesalazine—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CD40LG—systemic scleroderma	0.000666	0.00318	CbGpPWpGaD
Mesalazine—PTGS2—Spinal Cord Injury—RHOB—systemic scleroderma	0.000664	0.00317	CbGpPWpGaD
Mesalazine—PTGS2—Integrated Pancreatic Cancer Pathway—TOP1—systemic scleroderma	0.000655	0.00313	CbGpPWpGaD
Mesalazine—IKBKB—IL-1 signaling pathway—CCL2—systemic scleroderma	0.000654	0.00312	CbGpPWpGaD
Mesalazine—ALOX5—Selenium Micronutrient Network—IL1B—systemic scleroderma	0.000646	0.00308	CbGpPWpGaD
Mesalazine—IKBKB—TCR Signaling Pathway—IL1A—systemic scleroderma	0.000641	0.00306	CbGpPWpGaD
Mesalazine—CHUK—TWEAK Signaling Pathway—MMP9—systemic scleroderma	0.00064	0.00305	CbGpPWpGaD
Mesalazine—IKBKB—Interleukin-1 signaling—IL1B—systemic scleroderma	0.00064	0.00305	CbGpPWpGaD
Mesalazine—IKBKB—NOD pathway—IL1B—systemic scleroderma	0.000627	0.00299	CbGpPWpGaD
Mesalazine—CHUK—Signaling by Interleukins—IL1A—systemic scleroderma	0.000611	0.00292	CbGpPWpGaD
Mesalazine—PPARG—Fatty acid, triacylglycerol, and ketone body metabolism—CTGF—systemic scleroderma	0.000609	0.00291	CbGpPWpGaD
Mesalazine—CHUK—B Cell Activation—BLK—systemic scleroderma	0.000595	0.00284	CbGpPWpGaD
Mesalazine—CHUK—AGE/RAGE pathway—MMP2—systemic scleroderma	0.000593	0.00283	CbGpPWpGaD
Mesalazine—IKBKB—TWEAK Signaling Pathway—MMP9—systemic scleroderma	0.00058	0.00277	CbGpPWpGaD
Mesalazine—CHUK—AGE/RAGE pathway—NOS3—systemic scleroderma	0.000555	0.00265	CbGpPWpGaD
Mesalazine—IKBKB—Signaling by Interleukins—IL1A—systemic scleroderma	0.000554	0.00264	CbGpPWpGaD
Mesalazine—CHUK—IL-1 signaling pathway—IL1B—systemic scleroderma	0.000547	0.00261	CbGpPWpGaD
Mesalazine—IKBKB—B Cell Activation—BLK—systemic scleroderma	0.000539	0.00257	CbGpPWpGaD
Mesalazine—IKBKB—AGE/RAGE pathway—MMP2—systemic scleroderma	0.000537	0.00256	CbGpPWpGaD
Mesalazine—PPARG—Generic Transcription Pathway—SMAD7—systemic scleroderma	0.000522	0.00249	CbGpPWpGaD
Mesalazine—ALOX5—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	0.000517	0.00247	CbGpPWpGaD
Mesalazine—CHUK—Interleukin-11 Signaling Pathway—TGFB1—systemic scleroderma	0.000508	0.00242	CbGpPWpGaD
Mesalazine—IKBKB—AGE/RAGE pathway—NOS3—systemic scleroderma	0.000504	0.0024	CbGpPWpGaD
Mesalazine—CHUK—Cytokine Signaling in Immune system—IRF5—systemic scleroderma	0.000503	0.0024	CbGpPWpGaD
Mesalazine—CHUK—Leptin signaling pathway—NOS3—systemic scleroderma	0.000501	0.00239	CbGpPWpGaD
Mesalazine—IKBKB—IL-1 signaling pathway—IL1B—systemic scleroderma	0.000496	0.00237	CbGpPWpGaD
Mesalazine—CHUK—Cytokine Signaling in Immune system—IRF8—systemic scleroderma	0.000481	0.0023	CbGpPWpGaD
Mesalazine—CHUK—TNF alpha Signaling Pathway—CCL2—systemic scleroderma	0.000478	0.00228	CbGpPWpGaD
Mesalazine—IKBKB—Interleukin-11 Signaling Pathway—TGFB1—systemic scleroderma	0.000461	0.0022	CbGpPWpGaD
Mesalazine—IKBKB—Cytokine Signaling in Immune system—IRF5—systemic scleroderma	0.000456	0.00218	CbGpPWpGaD
Mesalazine—IKBKB—Leptin signaling pathway—NOS3—systemic scleroderma	0.000455	0.00217	CbGpPWpGaD
Mesalazine—CHUK—AGE/RAGE pathway—MMP9—systemic scleroderma	0.000446	0.00213	CbGpPWpGaD
Mesalazine—IKBKB—Cytokine Signaling in Immune system—IRF8—systemic scleroderma	0.000436	0.00208	CbGpPWpGaD
Mesalazine—IKBKB—TNF alpha Signaling Pathway—CCL2—systemic scleroderma	0.000433	0.00207	CbGpPWpGaD
Mesalazine—CHUK—Leptin signaling pathway—IL1B—systemic scleroderma	0.000427	0.00204	CbGpPWpGaD
Mesalazine—CHUK—Cardiac Hypertrophic Response—TGFB1—systemic scleroderma	0.000425	0.00203	CbGpPWpGaD
Mesalazine—IKBKB—AGE/RAGE pathway—MMP9—systemic scleroderma	0.000404	0.00193	CbGpPWpGaD
Mesalazine—CHUK—Integrated Breast Cancer Pathway—MMP1—systemic scleroderma	0.000395	0.00189	CbGpPWpGaD
Mesalazine—ALOX5—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	0.000392	0.00187	CbGpPWpGaD
Mesalazine—IKBKB—MAPK Signaling Pathway—IL1A—systemic scleroderma	0.000389	0.00186	CbGpPWpGaD
Mesalazine—IKBKB—Leptin signaling pathway—IL1B—systemic scleroderma	0.000387	0.00185	CbGpPWpGaD
Mesalazine—IKBKB—Cardiac Hypertrophic Response—TGFB1—systemic scleroderma	0.000385	0.00184	CbGpPWpGaD
Mesalazine—PPARG—Developmental Biology—RHOB—systemic scleroderma	0.00038	0.00181	CbGpPWpGaD
Mesalazine—PTGS1—Selenium Micronutrient Network—CCL2—systemic scleroderma	0.000369	0.00176	CbGpPWpGaD
Mesalazine—CHUK—TCR Signaling Pathway—IL1B—systemic scleroderma	0.000369	0.00176	CbGpPWpGaD
Mesalazine—PPARG—Transcriptional regulation of white adipocyte differentiation—TGFB1—systemic scleroderma	0.000346	0.00165	CbGpPWpGaD
Mesalazine—PTGS2—Spinal Cord Injury—IL1A—systemic scleroderma	0.000337	0.00161	CbGpPWpGaD
Mesalazine—IKBKB—TCR Signaling Pathway—IL1B—systemic scleroderma	0.000334	0.0016	CbGpPWpGaD
Mesalazine—CHUK—Toll-like Receptor Signaling Pathway—IL1B—systemic scleroderma	0.000334	0.00159	CbGpPWpGaD
Mesalazine—PPARG—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	0.00032	0.00153	CbGpPWpGaD
Mesalazine—CHUK—Signaling by Interleukins—IL1B—systemic scleroderma	0.000319	0.00152	CbGpPWpGaD
Mesalazine—CHUK—MicroRNAs in cardiomyocyte hypertrophy—TGFB1—systemic scleroderma	0.000303	0.00144	CbGpPWpGaD
Mesalazine—IKBKB—Toll-like Receptor Signaling Pathway—IL1B—systemic scleroderma	0.000302	0.00144	CbGpPWpGaD
Mesalazine—CHUK—Cytokine Signaling in Immune system—HLA-DQB1—systemic scleroderma	0.0003	0.00143	CbGpPWpGaD
Mesalazine—PTGS2—Selenium Micronutrient Network—CCL2—systemic scleroderma	0.000293	0.0014	CbGpPWpGaD
Mesalazine—IKBKB—Signaling by Interleukins—IL1B—systemic scleroderma	0.000289	0.00138	CbGpPWpGaD
Mesalazine—PPARG—Generic Transcription Pathway—CTGF—systemic scleroderma	0.000288	0.00138	CbGpPWpGaD
Mesalazine—CHUK—TCR Signaling Pathway—TGFB1—systemic scleroderma	0.000287	0.00137	CbGpPWpGaD
Mesalazine—CHUK—Cytokine Signaling in Immune system—IL1A—systemic scleroderma	0.000285	0.00136	CbGpPWpGaD
Mesalazine—PTGS1—Selenium Micronutrient Network—IL1B—systemic scleroderma	0.00028	0.00134	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—CSK—systemic scleroderma	0.000276	0.00131	CbGpPWpGaD
Mesalazine—IKBKB—MicroRNAs in cardiomyocyte hypertrophy—TGFB1—systemic scleroderma	0.000275	0.00131	CbGpPWpGaD
Mesalazine—IKBKB—Cytokine Signaling in Immune system—HLA-DQB1—systemic scleroderma	0.000272	0.0013	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—ITGAM—systemic scleroderma	0.00027	0.00129	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—CD247—systemic scleroderma	0.00027	0.00129	CbGpPWpGaD
Mesalazine—CHUK—Regulation of toll-like receptor signaling pathway—IL1B—systemic scleroderma	0.00026	0.00124	CbGpPWpGaD
Mesalazine—IKBKB—TCR Signaling Pathway—TGFB1—systemic scleroderma	0.00026	0.00124	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—CD247—systemic scleroderma	0.000259	0.00124	CbGpPWpGaD
Mesalazine—IKBKB—Cytokine Signaling in Immune system—IL1A—systemic scleroderma	0.000259	0.00123	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—TNFAIP3—systemic scleroderma	0.000253	0.00121	CbGpPWpGaD
Mesalazine—PPARG—Gene Expression—SMAD7—systemic scleroderma	0.000251	0.0012	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—CSK—systemic scleroderma	0.00025	0.00119	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—ITGAM—systemic scleroderma	0.000245	0.00117	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—CD247—systemic scleroderma	0.000245	0.00117	CbGpPWpGaD
Mesalazine—CHUK—Signaling by SCF-KIT—MMP9—systemic scleroderma	0.000243	0.00116	CbGpPWpGaD
Mesalazine—PPARG—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	0.000243	0.00116	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—BLK—systemic scleroderma	0.00024	0.00114	CbGpPWpGaD
Mesalazine—IKBKB—Regulation of toll-like receptor signaling pathway—IL1B—systemic scleroderma	0.000236	0.00113	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—CD247—systemic scleroderma	0.000235	0.00112	CbGpPWpGaD
Mesalazine—PPARG—Gene Expression—TNFSF13—systemic scleroderma	0.000234	0.00111	CbGpPWpGaD
Mesalazine—PTGS2—Spinal Cord Injury—CCL2—systemic scleroderma	0.000232	0.00111	CbGpPWpGaD
Mesalazine—ALOX5—Metabolism—HSPG2—systemic scleroderma	0.00023	0.0011	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—TNFAIP3—systemic scleroderma	0.000229	0.00109	CbGpPWpGaD
Mesalazine—PPARG—Adipogenesis—TGFB1—systemic scleroderma	0.000227	0.00109	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	0.000224	0.00107	CbGpPWpGaD
Mesalazine—PTGS2—Selenium Micronutrient Network—IL1B—systemic scleroderma	0.000222	0.00106	CbGpPWpGaD
Mesalazine—CHUK—Disease—SMAD7—systemic scleroderma	0.000219	0.00104	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—BLK—systemic scleroderma	0.000217	0.00104	CbGpPWpGaD
Mesalazine—IKBKB—MAPK Signaling Pathway—IL1B—systemic scleroderma	0.000203	0.000968	CbGpPWpGaD
Mesalazine—Body temperature increased—Leflunomide—systemic scleroderma	0.000202	0.000344	CcSEcCtD
Mesalazine—Feeling abnormal—Mycophenolic acid—systemic scleroderma	0.000201	0.000342	CcSEcCtD
Mesalazine—Chest pain—Mycophenolate mofetil—systemic scleroderma	0.000201	0.000341	CcSEcCtD
Mesalazine—Myalgia—Mycophenolate mofetil—systemic scleroderma	0.000201	0.000341	CcSEcCtD
Mesalazine—Arthralgia—Mycophenolate mofetil—systemic scleroderma	0.000201	0.000341	CcSEcCtD
Mesalazine—Neuropathy peripheral—Prednisone—systemic scleroderma	0.000201	0.000341	CcSEcCtD
Mesalazine—Breast disorder—Methotrexate—systemic scleroderma	0.0002	0.000341	CcSEcCtD
Mesalazine—CHUK—Disease—TGFBI—systemic scleroderma	0.0002	0.000956	CbGpPWpGaD
Mesalazine—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	0.0002	0.00034	CcSEcCtD
Mesalazine—Anxiety—Mycophenolate mofetil—systemic scleroderma	0.0002	0.00034	CcSEcCtD
Mesalazine—Hypersensitivity—Azathioprine—systemic scleroderma	0.000199	0.000339	CcSEcCtD
Mesalazine—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	0.000199	0.000339	CcSEcCtD
Mesalazine—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	0.000199	0.000339	CcSEcCtD
Mesalazine—Insomnia—Lisinopril—systemic scleroderma	0.000199	0.000338	CcSEcCtD
Mesalazine—Discomfort—Mycophenolate mofetil—systemic scleroderma	0.000198	0.000337	CcSEcCtD
Mesalazine—Paraesthesia—Lisinopril—systemic scleroderma	0.000197	0.000336	CcSEcCtD
Mesalazine—Vomiting—Captopril—systemic scleroderma	0.000197	0.000335	CcSEcCtD
Mesalazine—Dry mouth—Mycophenolate mofetil—systemic scleroderma	0.000196	0.000334	CcSEcCtD
Mesalazine—CHUK—Adaptive Immune System—CTLA4—systemic scleroderma	0.000196	0.000937	CbGpPWpGaD
Mesalazine—Dyspnoea—Lisinopril—systemic scleroderma	0.000196	0.000333	CcSEcCtD
Mesalazine—Rash—Captopril—systemic scleroderma	0.000196	0.000333	CcSEcCtD
Mesalazine—Dermatitis—Captopril—systemic scleroderma	0.000195	0.000332	CcSEcCtD
Mesalazine—Somnolence—Lisinopril—systemic scleroderma	0.000195	0.000332	CcSEcCtD
Mesalazine—Headache—Captopril—systemic scleroderma	0.000194	0.000331	CcSEcCtD
Mesalazine—Confusional state—Mycophenolate mofetil—systemic scleroderma	0.000194	0.00033	CcSEcCtD
Mesalazine—Dyspepsia—Lisinopril—systemic scleroderma	0.000193	0.000329	CcSEcCtD
Mesalazine—Abdominal pain—Mycophenolic acid—systemic scleroderma	0.000193	0.000328	CcSEcCtD
Mesalazine—Body temperature increased—Mycophenolic acid—systemic scleroderma	0.000193	0.000328	CcSEcCtD
Mesalazine—Anaphylactic shock—Mycophenolate mofetil—systemic scleroderma	0.000192	0.000327	CcSEcCtD
Mesalazine—Oedema—Mycophenolate mofetil—systemic scleroderma	0.000192	0.000327	CcSEcCtD
Mesalazine—Asthma—Methotrexate—systemic scleroderma	0.000192	0.000326	CcSEcCtD
Mesalazine—Infection—Mycophenolate mofetil—systemic scleroderma	0.000191	0.000325	CcSEcCtD
Mesalazine—Decreased appetite—Lisinopril—systemic scleroderma	0.000191	0.000325	CcSEcCtD
Mesalazine—Eosinophilia—Methotrexate—systemic scleroderma	0.00019	0.000323	CcSEcCtD
Mesalazine—Gastrointestinal disorder—Lisinopril—systemic scleroderma	0.00019	0.000323	CcSEcCtD
Mesalazine—Fatigue—Lisinopril—systemic scleroderma	0.000189	0.000322	CcSEcCtD
Mesalazine—Shock—Mycophenolate mofetil—systemic scleroderma	0.000189	0.000322	CcSEcCtD
Mesalazine—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	0.000189	0.000321	CcSEcCtD
Mesalazine—Thrombocytopenia—Mycophenolate mofetil—systemic scleroderma	0.000188	0.000321	CcSEcCtD
Mesalazine—Hypersensitivity—Leflunomide—systemic scleroderma	0.000188	0.00032	CcSEcCtD
Mesalazine—Pancreatitis—Methotrexate—systemic scleroderma	0.000188	0.00032	CcSEcCtD
Mesalazine—Constipation—Lisinopril—systemic scleroderma	0.000188	0.00032	CcSEcCtD
Mesalazine—Pain—Lisinopril—systemic scleroderma	0.000188	0.00032	CcSEcCtD
Mesalazine—Tachycardia—Mycophenolate mofetil—systemic scleroderma	0.000188	0.00032	CcSEcCtD
Mesalazine—Skin disorder—Mycophenolate mofetil—systemic scleroderma	0.000187	0.000318	CcSEcCtD
Mesalazine—Hyperhidrosis—Mycophenolate mofetil—systemic scleroderma	0.000186	0.000316	CcSEcCtD
Mesalazine—Diarrhoea—Azathioprine—systemic scleroderma	0.000185	0.000315	CcSEcCtD
Mesalazine—Haemoglobin—Prednisone—systemic scleroderma	0.000185	0.000314	CcSEcCtD
Mesalazine—Nausea—Captopril—systemic scleroderma	0.000184	0.000313	CcSEcCtD
Mesalazine—Abdominal discomfort—Methotrexate—systemic scleroderma	0.000184	0.000313	CcSEcCtD
Mesalazine—Haemorrhage—Prednisone—systemic scleroderma	0.000184	0.000312	CcSEcCtD
Mesalazine—Anorexia—Mycophenolate mofetil—systemic scleroderma	0.000183	0.000312	CcSEcCtD
Mesalazine—Asthenia—Leflunomide—systemic scleroderma	0.000183	0.000312	CcSEcCtD
Mesalazine—Pancytopenia—Methotrexate—systemic scleroderma	0.000182	0.00031	CcSEcCtD
Mesalazine—Feeling abnormal—Lisinopril—systemic scleroderma	0.000181	0.000308	CcSEcCtD
Mesalazine—Pruritus—Leflunomide—systemic scleroderma	0.000181	0.000308	CcSEcCtD
Mesalazine—Connective tissue disorder—Prednisone—systemic scleroderma	0.00018	0.000307	CcSEcCtD
Mesalazine—Hypotension—Mycophenolate mofetil—systemic scleroderma	0.00018	0.000306	CcSEcCtD
Mesalazine—Gastrointestinal pain—Lisinopril—systemic scleroderma	0.00018	0.000306	CcSEcCtD
Mesalazine—Neutropenia—Methotrexate—systemic scleroderma	0.000179	0.000305	CcSEcCtD
Mesalazine—Dysuria—Methotrexate—systemic scleroderma	0.000179	0.000305	CcSEcCtD
Mesalazine—Dizziness—Azathioprine—systemic scleroderma	0.000179	0.000304	CcSEcCtD
Mesalazine—Upper respiratory tract infection—Methotrexate—systemic scleroderma	0.000178	0.000303	CcSEcCtD
Mesalazine—IKBKB—Adaptive Immune System—CTLA4—systemic scleroderma	0.000178	0.000849	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	0.000178	0.000849	CbGpPWpGaD
Mesalazine—PTGS2—Spinal Cord Injury—IL1B—systemic scleroderma	0.000176	0.000839	CbGpPWpGaD
Mesalazine—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	0.000175	0.000298	CcSEcCtD
Mesalazine—Photosensitivity reaction—Methotrexate—systemic scleroderma	0.000175	0.000298	CcSEcCtD
Mesalazine—Asthenia—Mycophenolic acid—systemic scleroderma	0.000175	0.000298	CcSEcCtD
Mesalazine—Diarrhoea—Leflunomide—systemic scleroderma	0.000175	0.000298	CcSEcCtD
Mesalazine—Urticaria—Lisinopril—systemic scleroderma	0.000175	0.000297	CcSEcCtD
Mesalazine—ALOX5—Metabolism—CTGF—systemic scleroderma	0.000174	0.000833	CbGpPWpGaD
Mesalazine—Insomnia—Mycophenolate mofetil—systemic scleroderma	0.000174	0.000296	CcSEcCtD
Mesalazine—Abdominal pain—Lisinopril—systemic scleroderma	0.000174	0.000295	CcSEcCtD
Mesalazine—Body temperature increased—Lisinopril—systemic scleroderma	0.000174	0.000295	CcSEcCtD
Mesalazine—Paraesthesia—Mycophenolate mofetil—systemic scleroderma	0.000173	0.000294	CcSEcCtD
Mesalazine—Pruritus—Mycophenolic acid—systemic scleroderma	0.000173	0.000293	CcSEcCtD
Mesalazine—Vomiting—Azathioprine—systemic scleroderma	0.000172	0.000293	CcSEcCtD
Mesalazine—Pneumonia—Methotrexate—systemic scleroderma	0.000172	0.000292	CcSEcCtD
Mesalazine—Eye disorder—Prednisone—systemic scleroderma	0.000172	0.000292	CcSEcCtD
Mesalazine—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	0.000172	0.000292	CcSEcCtD
Mesalazine—Somnolence—Mycophenolate mofetil—systemic scleroderma	0.000171	0.000291	CcSEcCtD
Mesalazine—Infestation NOS—Methotrexate—systemic scleroderma	0.000171	0.000291	CcSEcCtD
Mesalazine—Infestation—Methotrexate—systemic scleroderma	0.000171	0.000291	CcSEcCtD
Mesalazine—Rash—Azathioprine—systemic scleroderma	0.000171	0.00029	CcSEcCtD
Mesalazine—Dermatitis—Azathioprine—systemic scleroderma	0.000171	0.00029	CcSEcCtD
Mesalazine—Depression—Methotrexate—systemic scleroderma	0.00017	0.00029	CcSEcCtD
Mesalazine—PTGS1—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	0.00017	0.000811	CbGpPWpGaD
Mesalazine—Headache—Azathioprine—systemic scleroderma	0.00017	0.000288	CcSEcCtD
Mesalazine—Stevens-Johnson syndrome—Methotrexate—systemic scleroderma	0.00017	0.000288	CcSEcCtD
Mesalazine—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	0.000169	0.000288	CcSEcCtD
Mesalazine—Dizziness—Leflunomide—systemic scleroderma	0.000169	0.000288	CcSEcCtD
Mesalazine—Renal failure—Methotrexate—systemic scleroderma	0.000168	0.000286	CcSEcCtD
Mesalazine—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	0.000167	0.000285	CcSEcCtD
Mesalazine—CHUK—Immune System—CSK—systemic scleroderma	0.000167	0.000797	CbGpPWpGaD
Mesalazine—Diarrhoea—Mycophenolic acid—systemic scleroderma	0.000167	0.000284	CcSEcCtD
Mesalazine—Stomatitis—Methotrexate—systemic scleroderma	0.000167	0.000283	CcSEcCtD
Mesalazine—Angiopathy—Prednisone—systemic scleroderma	0.000167	0.000283	CcSEcCtD
Mesalazine—Conjunctivitis—Methotrexate—systemic scleroderma	0.000166	0.000283	CcSEcCtD
Mesalazine—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	0.000166	0.000283	CcSEcCtD
Mesalazine—Immune system disorder—Prednisone—systemic scleroderma	0.000166	0.000282	CcSEcCtD
Mesalazine—PTGS2—Spinal Cord Injury—MMP9—systemic scleroderma	0.000166	0.000791	CbGpPWpGaD
Mesalazine—Pain—Mycophenolate mofetil—systemic scleroderma	0.000165	0.00028	CcSEcCtD
Mesalazine—Constipation—Mycophenolate mofetil—systemic scleroderma	0.000165	0.00028	CcSEcCtD
Mesalazine—CHUK—Immune System—IRF5—systemic scleroderma	0.000164	0.000784	CbGpPWpGaD
Mesalazine—Sweating—Methotrexate—systemic scleroderma	0.000164	0.000279	CcSEcCtD
Mesalazine—Haematuria—Methotrexate—systemic scleroderma	0.000163	0.000277	CcSEcCtD
Mesalazine—Vomiting—Leflunomide—systemic scleroderma	0.000163	0.000276	CcSEcCtD
Mesalazine—Alopecia—Prednisone—systemic scleroderma	0.000162	0.000276	CcSEcCtD
Mesalazine—Hypersensitivity—Lisinopril—systemic scleroderma	0.000162	0.000275	CcSEcCtD
Mesalazine—Hepatobiliary disease—Methotrexate—systemic scleroderma	0.000162	0.000275	CcSEcCtD
Mesalazine—CHUK—Adaptive Immune System—HLA-DQB1—systemic scleroderma	0.000162	0.000771	CbGpPWpGaD
Mesalazine—Dizziness—Mycophenolic acid—systemic scleroderma	0.000161	0.000274	CcSEcCtD
Mesalazine—Epistaxis—Methotrexate—systemic scleroderma	0.000161	0.000274	CcSEcCtD
Mesalazine—Rash—Leflunomide—systemic scleroderma	0.000161	0.000274	CcSEcCtD
Mesalazine—Dermatitis—Leflunomide—systemic scleroderma	0.000161	0.000274	CcSEcCtD
Mesalazine—Mental disorder—Prednisone—systemic scleroderma	0.000161	0.000274	CcSEcCtD
Mesalazine—Nausea—Azathioprine—systemic scleroderma	0.000161	0.000273	CcSEcCtD
Mesalazine—Headache—Leflunomide—systemic scleroderma	0.00016	0.000272	CcSEcCtD
Mesalazine—Erythema—Prednisone—systemic scleroderma	0.00016	0.000272	CcSEcCtD
Mesalazine—CHUK—Disease—HSPG2—systemic scleroderma	0.00016	0.000762	CbGpPWpGaD
Mesalazine—Agranulocytosis—Methotrexate—systemic scleroderma	0.00016	0.000271	CcSEcCtD
Mesalazine—Feeling abnormal—Mycophenolate mofetil—systemic scleroderma	0.000159	0.00027	CcSEcCtD
Mesalazine—IKBKB—MAPK Signaling Pathway—TGFB1—systemic scleroderma	0.000158	0.000752	CbGpPWpGaD
Mesalazine—Asthenia—Lisinopril—systemic scleroderma	0.000158	0.000268	CcSEcCtD
Mesalazine—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	0.000157	0.000268	CcSEcCtD
Mesalazine—CHUK—Immune System—IRF8—systemic scleroderma	0.000157	0.00075	CbGpPWpGaD
Mesalazine—CHUK—Immune System—ITGAM—systemic scleroderma	0.000157	0.00075	CbGpPWpGaD
Mesalazine—CHUK—Immune System—CD247—systemic scleroderma	0.000157	0.00075	CbGpPWpGaD
Mesalazine—CHUK—Integrated Pancreatic Cancer Pathway—TGFB1—systemic scleroderma	0.000157	0.000749	CbGpPWpGaD
Mesalazine—Pruritus—Lisinopril—systemic scleroderma	0.000155	0.000264	CcSEcCtD
Mesalazine—Vomiting—Mycophenolic acid—systemic scleroderma	0.000155	0.000264	CcSEcCtD
Mesalazine—CHUK—Disease—CSK—systemic scleroderma	0.000154	0.000736	CbGpPWpGaD
Mesalazine—Haemoglobin—Methotrexate—systemic scleroderma	0.000154	0.000262	CcSEcCtD
Mesalazine—Rash—Mycophenolic acid—systemic scleroderma	0.000154	0.000262	CcSEcCtD
Mesalazine—Dermatitis—Mycophenolic acid—systemic scleroderma	0.000154	0.000261	CcSEcCtD
Mesalazine—Haemorrhage—Methotrexate—systemic scleroderma	0.000153	0.000261	CcSEcCtD
Mesalazine—Hepatitis—Methotrexate—systemic scleroderma	0.000153	0.000261	CcSEcCtD
Mesalazine—CHUK—Signaling Pathways—SMAD7—systemic scleroderma	0.000153	0.000732	CbGpPWpGaD
Mesalazine—Urticaria—Mycophenolate mofetil—systemic scleroderma	0.000153	0.00026	CcSEcCtD
Mesalazine—Headache—Mycophenolic acid—systemic scleroderma	0.000153	0.00026	CcSEcCtD
Mesalazine—CHUK—Adaptive Immune System—CD40LG—systemic scleroderma	0.000153	0.000729	CbGpPWpGaD
Mesalazine—Pharyngitis—Methotrexate—systemic scleroderma	0.000152	0.000259	CcSEcCtD
Mesalazine—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	0.000152	0.000259	CcSEcCtD
Mesalazine—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	0.000152	0.000259	CcSEcCtD
Mesalazine—Nausea—Leflunomide—systemic scleroderma	0.000152	0.000258	CcSEcCtD
Mesalazine—Urinary tract disorder—Methotrexate—systemic scleroderma	0.000152	0.000258	CcSEcCtD
Mesalazine—IKBKB—Immune System—CSK—systemic scleroderma	0.000152	0.000723	CbGpPWpGaD
Mesalazine—Vision blurred—Prednisone—systemic scleroderma	0.000151	0.000256	CcSEcCtD
Mesalazine—Urethral disorder—Methotrexate—systemic scleroderma	0.00015	0.000256	CcSEcCtD
Mesalazine—Diarrhoea—Lisinopril—systemic scleroderma	0.00015	0.000256	CcSEcCtD
Mesalazine—IKBKB—Immune System—IRF5—systemic scleroderma	0.000149	0.000711	CbGpPWpGaD
Mesalazine—CHUK—Cytokine Signaling in Immune system—IL1B—systemic scleroderma	0.000149	0.00071	CbGpPWpGaD
Mesalazine—Ill-defined disorder—Prednisone—systemic scleroderma	0.000148	0.000252	CcSEcCtD
Mesalazine—Anaemia—Prednisone—systemic scleroderma	0.000148	0.000251	CcSEcCtD
Mesalazine—CHUK—Immune System—TNFAIP3—systemic scleroderma	0.000147	0.000702	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—HLA-DQB1—systemic scleroderma	0.000147	0.000699	CbGpPWpGaD
Mesalazine—Angioedema—Prednisone—systemic scleroderma	0.000146	0.000248	CcSEcCtD
Mesalazine—CHUK—Immune System—BLK—systemic scleroderma	0.000145	0.000694	CbGpPWpGaD
Mesalazine—Dizziness—Lisinopril—systemic scleroderma	0.000145	0.000247	CcSEcCtD
Mesalazine—Erythema multiforme—Methotrexate—systemic scleroderma	0.000145	0.000247	CcSEcCtD
Mesalazine—CHUK—Disease—CD247—systemic scleroderma	0.000145	0.000692	CbGpPWpGaD
Mesalazine—Nausea—Mycophenolic acid—systemic scleroderma	0.000145	0.000246	CcSEcCtD
Mesalazine—Malaise—Prednisone—systemic scleroderma	0.000144	0.000245	CcSEcCtD
Mesalazine—Vertigo—Prednisone—systemic scleroderma	0.000144	0.000244	CcSEcCtD
Mesalazine—Eye disorder—Methotrexate—systemic scleroderma	0.000143	0.000244	CcSEcCtD
Mesalazine—Syncope—Prednisone—systemic scleroderma	0.000143	0.000244	CcSEcCtD
Mesalazine—Tinnitus—Methotrexate—systemic scleroderma	0.000143	0.000243	CcSEcCtD
Mesalazine—PPARG—Metabolism—HSPG2—systemic scleroderma	0.000143	0.00068	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—IRF8—systemic scleroderma	0.000142	0.00068	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—ITGAM—systemic scleroderma	0.000142	0.00068	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—CD247—systemic scleroderma	0.000142	0.00068	CbGpPWpGaD
Mesalazine—Cardiac disorder—Methotrexate—systemic scleroderma	0.000142	0.000242	CcSEcCtD
Mesalazine—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	0.000142	0.000241	CcSEcCtD
Mesalazine—Loss of consciousness—Prednisone—systemic scleroderma	0.000141	0.000239	CcSEcCtD
Mesalazine—Vomiting—Lisinopril—systemic scleroderma	0.00014	0.000238	CcSEcCtD
Mesalazine—Angiopathy—Methotrexate—systemic scleroderma	0.000139	0.000237	CcSEcCtD
Mesalazine—IKBKB—Signaling Pathways—SMAD7—systemic scleroderma	0.000139	0.000664	CbGpPWpGaD
Mesalazine—PPARG—Gene Expression—CTGF—systemic scleroderma	0.000139	0.000663	CbGpPWpGaD
Mesalazine—Immune system disorder—Methotrexate—systemic scleroderma	0.000139	0.000236	CcSEcCtD
Mesalazine—Rash—Lisinopril—systemic scleroderma	0.000139	0.000236	CcSEcCtD
Mesalazine—IKBKB—Adaptive Immune System—CD40LG—systemic scleroderma	0.000138	0.000661	CbGpPWpGaD
Mesalazine—Dermatitis—Lisinopril—systemic scleroderma	0.000138	0.000235	CcSEcCtD
Mesalazine—Mediastinal disorder—Methotrexate—systemic scleroderma	0.000138	0.000235	CcSEcCtD
Mesalazine—Asthenia—Mycophenolate mofetil—systemic scleroderma	0.000138	0.000235	CcSEcCtD
Mesalazine—Hypertension—Prednisone—systemic scleroderma	0.000138	0.000235	CcSEcCtD
Mesalazine—Chills—Methotrexate—systemic scleroderma	0.000138	0.000234	CcSEcCtD
Mesalazine—Headache—Lisinopril—systemic scleroderma	0.000138	0.000234	CcSEcCtD
Mesalazine—PTGS2—Spinal Cord Injury—TGFB1—systemic scleroderma	0.000137	0.000652	CbGpPWpGaD
Mesalazine—Pruritus—Mycophenolate mofetil—systemic scleroderma	0.000136	0.000232	CcSEcCtD
Mesalazine—Myalgia—Prednisone—systemic scleroderma	0.000136	0.000231	CcSEcCtD
Mesalazine—Arthralgia—Prednisone—systemic scleroderma	0.000136	0.000231	CcSEcCtD
Mesalazine—Anxiety—Prednisone—systemic scleroderma	0.000136	0.000231	CcSEcCtD
Mesalazine—Alopecia—Methotrexate—systemic scleroderma	0.000136	0.000231	CcSEcCtD
Mesalazine—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	0.000135	0.00023	CcSEcCtD
Mesalazine—PTGS2—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	0.000135	0.000644	CbGpPWpGaD
Mesalazine—IKBKB—Cytokine Signaling in Immune system—IL1B—systemic scleroderma	0.000135	0.000643	CbGpPWpGaD
Mesalazine—Discomfort—Prednisone—systemic scleroderma	0.000134	0.000229	CcSEcCtD
Mesalazine—Mental disorder—Methotrexate—systemic scleroderma	0.000134	0.000229	CcSEcCtD
Mesalazine—Erythema—Methotrexate—systemic scleroderma	0.000134	0.000227	CcSEcCtD
Mesalazine—IKBKB—Immune System—TNFAIP3—systemic scleroderma	0.000133	0.000637	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—BLK—systemic scleroderma	0.000132	0.000629	CbGpPWpGaD
Mesalazine—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	0.000132	0.000224	CcSEcCtD
Mesalazine—Dysgeusia—Methotrexate—systemic scleroderma	0.000131	0.000223	CcSEcCtD
Mesalazine—Nausea—Lisinopril—systemic scleroderma	0.000131	0.000222	CcSEcCtD
Mesalazine—Oedema—Prednisone—systemic scleroderma	0.00013	0.000222	CcSEcCtD
Mesalazine—Anaphylactic shock—Prednisone—systemic scleroderma	0.00013	0.000222	CcSEcCtD
Mesalazine—PTGS2—Disease—SMAD7—systemic scleroderma	0.00013	0.000619	CbGpPWpGaD
Mesalazine—Infection—Prednisone—systemic scleroderma	0.00013	0.00022	CcSEcCtD
Mesalazine—Back pain—Methotrexate—systemic scleroderma	0.000129	0.00022	CcSEcCtD
Mesalazine—Shock—Prednisone—systemic scleroderma	0.000128	0.000218	CcSEcCtD
Mesalazine—Nervous system disorder—Prednisone—systemic scleroderma	0.000128	0.000218	CcSEcCtD
Mesalazine—Tachycardia—Prednisone—systemic scleroderma	0.000127	0.000217	CcSEcCtD
Mesalazine—Dizziness—Mycophenolate mofetil—systemic scleroderma	0.000127	0.000216	CcSEcCtD
Mesalazine—Skin disorder—Prednisone—systemic scleroderma	0.000127	0.000216	CcSEcCtD
Mesalazine—PPARG—Developmental Biology—MMP2—systemic scleroderma	0.000126	0.000602	CbGpPWpGaD
Mesalazine—Hyperhidrosis—Prednisone—systemic scleroderma	0.000126	0.000215	CcSEcCtD
Mesalazine—Vision blurred—Methotrexate—systemic scleroderma	0.000126	0.000214	CcSEcCtD
Mesalazine—Anorexia—Prednisone—systemic scleroderma	0.000124	0.000212	CcSEcCtD
Mesalazine—Ill-defined disorder—Methotrexate—systemic scleroderma	0.000124	0.000211	CcSEcCtD
Mesalazine—Anaemia—Methotrexate—systemic scleroderma	0.000123	0.00021	CcSEcCtD
Mesalazine—Vomiting—Mycophenolate mofetil—systemic scleroderma	0.000122	0.000208	CcSEcCtD
Mesalazine—Rash—Mycophenolate mofetil—systemic scleroderma	0.000121	0.000206	CcSEcCtD
Mesalazine—Dermatitis—Mycophenolate mofetil—systemic scleroderma	0.000121	0.000206	CcSEcCtD
Mesalazine—Headache—Mycophenolate mofetil—systemic scleroderma	0.000121	0.000205	CcSEcCtD
Mesalazine—Malaise—Methotrexate—systemic scleroderma	0.00012	0.000205	CcSEcCtD
Mesalazine—Vertigo—Methotrexate—systemic scleroderma	0.00012	0.000204	CcSEcCtD
Mesalazine—Leukopenia—Methotrexate—systemic scleroderma	0.00012	0.000203	CcSEcCtD
Mesalazine—CHUK—Immune System—CTLA4—systemic scleroderma	0.000119	0.000568	CbGpPWpGaD
Mesalazine—Musculoskeletal discomfort—Prednisone—systemic scleroderma	0.000119	0.000202	CcSEcCtD
Mesalazine—PTGS2—Disease—TGFBI—systemic scleroderma	0.000119	0.000566	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—RHOB—systemic scleroderma	0.000119	0.000566	CbGpPWpGaD
Mesalazine—Insomnia—Prednisone—systemic scleroderma	0.000118	0.000201	CcSEcCtD
Mesalazine—Paraesthesia—Prednisone—systemic scleroderma	0.000117	0.000199	CcSEcCtD
Mesalazine—Cough—Methotrexate—systemic scleroderma	0.000117	0.000198	CcSEcCtD
Mesalazine—Dyspepsia—Prednisone—systemic scleroderma	0.000115	0.000195	CcSEcCtD
Mesalazine—Nausea—Mycophenolate mofetil—systemic scleroderma	0.000114	0.000194	CcSEcCtD
Mesalazine—Myalgia—Methotrexate—systemic scleroderma	0.000114	0.000193	CcSEcCtD
Mesalazine—Arthralgia—Methotrexate—systemic scleroderma	0.000114	0.000193	CcSEcCtD
Mesalazine—Chest pain—Methotrexate—systemic scleroderma	0.000114	0.000193	CcSEcCtD
Mesalazine—Decreased appetite—Prednisone—systemic scleroderma	0.000113	0.000193	CcSEcCtD
Mesalazine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	0.000113	0.000192	CcSEcCtD
Mesalazine—Fatigue—Prednisone—systemic scleroderma	0.000112	0.000191	CcSEcCtD
Mesalazine—Discomfort—Methotrexate—systemic scleroderma	0.000112	0.000191	CcSEcCtD
Mesalazine—CHUK—Signaling Pathways—HSPG2—systemic scleroderma	0.000112	0.000534	CbGpPWpGaD
Mesalazine—Constipation—Prednisone—systemic scleroderma	0.000112	0.00019	CcSEcCtD
Mesalazine—Confusional state—Methotrexate—systemic scleroderma	0.00011	0.000187	CcSEcCtD
Mesalazine—Anaphylactic shock—Methotrexate—systemic scleroderma	0.000109	0.000185	CcSEcCtD
Mesalazine—Infection—Methotrexate—systemic scleroderma	0.000108	0.000184	CcSEcCtD
Mesalazine—CHUK—Signaling Pathways—CSK—systemic scleroderma	0.000108	0.000516	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—CTGF—systemic scleroderma	0.000108	0.000515	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—CTLA4—systemic scleroderma	0.000108	0.000515	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—RHOB—systemic scleroderma	0.000108	0.000513	CbGpPWpGaD
Mesalazine—Feeling abnormal—Prednisone—systemic scleroderma	0.000108	0.000183	CcSEcCtD
Mesalazine—Nervous system disorder—Methotrexate—systemic scleroderma	0.000107	0.000182	CcSEcCtD
Mesalazine—Thrombocytopenia—Methotrexate—systemic scleroderma	0.000107	0.000182	CcSEcCtD
Mesalazine—Gastrointestinal pain—Prednisone—systemic scleroderma	0.000107	0.000181	CcSEcCtD
Mesalazine—Skin disorder—Methotrexate—systemic scleroderma	0.000106	0.00018	CcSEcCtD
Mesalazine—Hyperhidrosis—Methotrexate—systemic scleroderma	0.000105	0.000179	CcSEcCtD
Mesalazine—Anorexia—Methotrexate—systemic scleroderma	0.000104	0.000177	CcSEcCtD
Mesalazine—Urticaria—Prednisone—systemic scleroderma	0.000104	0.000176	CcSEcCtD
Mesalazine—Body temperature increased—Prednisone—systemic scleroderma	0.000103	0.000175	CcSEcCtD
Mesalazine—Abdominal pain—Prednisone—systemic scleroderma	0.000103	0.000175	CcSEcCtD
Mesalazine—Hypotension—Methotrexate—systemic scleroderma	0.000102	0.000173	CcSEcCtD
Mesalazine—IKBKB—Signaling Pathways—HSPG2—systemic scleroderma	0.000101	0.000484	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—HSPG2—systemic scleroderma	9.98e-05	0.000476	CbGpPWpGaD
Mesalazine—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	9.94e-05	0.000169	CcSEcCtD
Mesalazine—Insomnia—Methotrexate—systemic scleroderma	9.86e-05	0.000168	CcSEcCtD
Mesalazine—CHUK—Immune System—HLA-DQB1—systemic scleroderma	9.81e-05	0.000468	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—CSK—systemic scleroderma	9.8e-05	0.000467	CbGpPWpGaD
Mesalazine—Paraesthesia—Methotrexate—systemic scleroderma	9.79e-05	0.000167	CcSEcCtD
Mesalazine—Dyspnoea—Methotrexate—systemic scleroderma	9.72e-05	0.000165	CcSEcCtD
Mesalazine—Somnolence—Methotrexate—systemic scleroderma	9.69e-05	0.000165	CcSEcCtD
Mesalazine—Hypersensitivity—Prednisone—systemic scleroderma	9.61e-05	0.000163	CcSEcCtD
Mesalazine—Dyspepsia—Methotrexate—systemic scleroderma	9.6e-05	0.000163	CcSEcCtD
Mesalazine—PPARG—Developmental Biology—MMP9—systemic scleroderma	9.48e-05	0.000453	CbGpPWpGaD
Mesalazine—Decreased appetite—Methotrexate—systemic scleroderma	9.48e-05	0.000161	CcSEcCtD
Mesalazine—PTGS2—Disease—HSPG2—systemic scleroderma	9.46e-05	0.000452	CbGpPWpGaD
Mesalazine—Gastrointestinal disorder—Methotrexate—systemic scleroderma	9.41e-05	0.00016	CcSEcCtD
Mesalazine—Fatigue—Methotrexate—systemic scleroderma	9.4e-05	0.00016	CcSEcCtD
Mesalazine—Asthenia—Prednisone—systemic scleroderma	9.36e-05	0.000159	CcSEcCtD
Mesalazine—Pain—Methotrexate—systemic scleroderma	9.33e-05	0.000159	CcSEcCtD
Mesalazine—CHUK—Immune System—IL1A—systemic scleroderma	9.31e-05	0.000444	CbGpPWpGaD
Mesalazine—PTGS2—Integrated Pancreatic Cancer Pathway—TGFB1—systemic scleroderma	9.3e-05	0.000444	CbGpPWpGaD
Mesalazine—CHUK—Immune System—CD40LG—systemic scleroderma	9.26e-05	0.000442	CbGpPWpGaD
Mesalazine—Pruritus—Prednisone—systemic scleroderma	9.23e-05	0.000157	CcSEcCtD
Mesalazine—PTGS2—Disease—CSK—systemic scleroderma	9.14e-05	0.000436	CbGpPWpGaD
Mesalazine—Feeling abnormal—Methotrexate—systemic scleroderma	8.99e-05	0.000153	CcSEcCtD
Mesalazine—Diarrhoea—Prednisone—systemic scleroderma	8.93e-05	0.000152	CcSEcCtD
Mesalazine—Gastrointestinal pain—Methotrexate—systemic scleroderma	8.92e-05	0.000152	CcSEcCtD
Mesalazine—IKBKB—Immune System—HLA-DQB1—systemic scleroderma	8.89e-05	0.000424	CbGpPWpGaD
Mesalazine—Urticaria—Methotrexate—systemic scleroderma	8.66e-05	0.000147	CcSEcCtD
Mesalazine—Dizziness—Prednisone—systemic scleroderma	8.63e-05	0.000147	CcSEcCtD
Mesalazine—Body temperature increased—Methotrexate—systemic scleroderma	8.62e-05	0.000147	CcSEcCtD
Mesalazine—Abdominal pain—Methotrexate—systemic scleroderma	8.62e-05	0.000147	CcSEcCtD
Mesalazine—PTGS2—Disease—CD247—systemic scleroderma	8.59e-05	0.00041	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—IL1A—systemic scleroderma	8.45e-05	0.000403	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—CD40LG—systemic scleroderma	8.4e-05	0.000401	CbGpPWpGaD
Mesalazine—Vomiting—Prednisone—systemic scleroderma	8.3e-05	0.000141	CcSEcCtD
Mesalazine—Rash—Prednisone—systemic scleroderma	8.23e-05	0.00014	CcSEcCtD
Mesalazine—Dermatitis—Prednisone—systemic scleroderma	8.22e-05	0.00014	CcSEcCtD
Mesalazine—Headache—Prednisone—systemic scleroderma	8.17e-05	0.000139	CcSEcCtD
Mesalazine—Hypersensitivity—Methotrexate—systemic scleroderma	8.03e-05	0.000137	CcSEcCtD
Mesalazine—PTGS2—Metabolism—HSPG2—systemic scleroderma	7.93e-05	0.000378	CbGpPWpGaD
Mesalazine—Asthenia—Methotrexate—systemic scleroderma	7.82e-05	0.000133	CcSEcCtD
Mesalazine—PPARG—Developmental Biology—TGFB1—systemic scleroderma	7.82e-05	0.000373	CbGpPWpGaD
Mesalazine—Nausea—Prednisone—systemic scleroderma	7.75e-05	0.000132	CcSEcCtD
Mesalazine—Pruritus—Methotrexate—systemic scleroderma	7.72e-05	0.000131	CcSEcCtD
Mesalazine—ALOX5—Metabolism—NOS3—systemic scleroderma	7.59e-05	0.000362	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—CTGF—systemic scleroderma	7.57e-05	0.000361	CbGpPWpGaD
Mesalazine—Diarrhoea—Methotrexate—systemic scleroderma	7.46e-05	0.000127	CcSEcCtD
Mesalazine—Dizziness—Methotrexate—systemic scleroderma	7.21e-05	0.000123	CcSEcCtD
Mesalazine—Vomiting—Methotrexate—systemic scleroderma	6.93e-05	0.000118	CcSEcCtD
Mesalazine—Rash—Methotrexate—systemic scleroderma	6.88e-05	0.000117	CcSEcCtD
Mesalazine—Dermatitis—Methotrexate—systemic scleroderma	6.87e-05	0.000117	CcSEcCtD
Mesalazine—Headache—Methotrexate—systemic scleroderma	6.83e-05	0.000116	CcSEcCtD
Mesalazine—Nausea—Methotrexate—systemic scleroderma	6.48e-05	0.00011	CcSEcCtD
Mesalazine—CHUK—Signaling Pathways—EDN1—systemic scleroderma	6.06e-05	0.000289	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—CTGF—systemic scleroderma	6.01e-05	0.000287	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—EDN1—systemic scleroderma	5.49e-05	0.000262	CbGpPWpGaD
Mesalazine—CHUK—Disease—NOS3—systemic scleroderma	5.27e-05	0.000251	CbGpPWpGaD
Mesalazine—CHUK—Immune System—IL1B—systemic scleroderma	4.86e-05	0.000232	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—NOS3—systemic scleroderma	4.7e-05	0.000224	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—IL1B—systemic scleroderma	4.4e-05	0.00021	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—CCL2—systemic scleroderma	4.14e-05	0.000198	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—CCL2—systemic scleroderma	3.75e-05	0.000179	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—NOS3—systemic scleroderma	3.69e-05	0.000176	CbGpPWpGaD
Mesalazine—CHUK—Disease—TGFB1—systemic scleroderma	3.48e-05	0.000166	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—NOS3—systemic scleroderma	3.35e-05	0.00016	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—NOS3—systemic scleroderma	3.29e-05	0.000157	CbGpPWpGaD
Mesalazine—PTGS2—Disease—NOS3—systemic scleroderma	3.12e-05	0.000149	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—MMP9—systemic scleroderma	2.96e-05	0.000141	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—MMP9—systemic scleroderma	2.68e-05	0.000128	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—NOS3—systemic scleroderma	2.61e-05	0.000125	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—TGFB1—systemic scleroderma	2.44e-05	0.000116	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—TGFB1—systemic scleroderma	2.21e-05	0.000106	CbGpPWpGaD
Mesalazine—PTGS2—Disease—TGFB1—systemic scleroderma	2.06e-05	9.85e-05	CbGpPWpGaD
